DE-LYCRA
14.9.2021 16:12:07 CEST | Business Wire | Press release
The LYCRA Company , a global leader in innovative solutions for stretch and performance technologies for the apparel industry, introduces today a breakthrough technology, LYCRA® ADAPTIV fiber. This fiber allows garments to have a better fit for various lifestyles, movements and different body types. The accompanying new brand identity– LYCRA® ADAPTIV – was created to communicate these new and beneficial motion attributes.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210914005789/en/
Made from a revolutionary polymer, this patent-pending, adaptive fiber has a unique chemistry that allows it to adjust to a wearer’s functional needs in a hybrid manner. This means that when the wearer is at rest, the polymer adapts its compressive holding force to deliver the right fit, shape and control. And when the wearer is in motion, the polymer adapts its elasticity to deliver improved comfort in motion and a second-skin effect allowing the garment to stay in place better. Garments made with fabrics containing LYCRA® ADAPTIV fiber are durable and are also easier to put on and take off.
“Consumers are seeking garments that offer greater versatility -- from work to leisure to social, and also from season to season and year to year,” says Steve Stewart, chief brand and innovation officer at The LYCRA Company. “They want garments that can adapt to their individual needs and lifestyle as well as ones that can adapt to their unique body type, even when their body size or shape may change or fluctuate. LYCRA® ADAPTIV fiber is the answer to satisfy all of these consumer needs.”
The LYCRA Company has conducted internal studies to assess wear performance by comparing fabrics and garments containing LYCRA® ADAPTIV fiber versus the same fabrics and garments containing only generic spandex. Results show several advantages in using LYCRA® ADAPTIV fiber including comfort-in-motion and second skin performance accompanied by shape retention and greater freedom of movement with a comfortable hold. Size inclusivity is also a key benefit in that LYCRA® ADAPTIV fiber promotes one-size-fits-more. The softer stretch within the wearing zone allows for a widened fit window that covers a broader range of body shapes within a given size. This makes the one-size-fits-more approach, and the potential reduction of SKUs, a practical possibility.
“Size inclusivity is not a buzzword – it is increasingly important to today’s consumers,” says Deana Stankowski, strategic marketing director for active, intimates, and swim at The LYCRA Company. “Every consumer’s body is unique and they want clothes they feel were designed for them – clothes that increase their personal comfort as well as their confidence level. Size alone is an inadequate indication of body type and body shape. Therefore, traditionally-sized garments may not fit every consumer within that size. That’s what makes LYCRA® ADAPTIV fiber so revolutionary --- it allows garments made with this fiber to adapt to many body shapes within a size range.”
The LYCRA Company worked with DIP agency to develop a new LYCRA® sub-brand identity that communicates the “adaptive” nature of this new fiber. The global agency FCB was selected to develop the campaign “LYCRA® ADAPTIV fiber Adapts to your world.” The campaign leverages computer-generated graphics to promote the adaptive nature of this groundbreaking spandex (elastane) fiber innovation.
In addition, two upcoming trade events will support the launch of LYCRA® ADAPTIV fiber. LYCRA® ADAPTIV fiber will be launched in the Asia-Pacific region at The LYCRA Company’s pavilion at Intertextile Shanghai -- booth 1.1 – E51 located in Hall 1.1 -- taking place October 9-11 at the National Exhibition and Convention Center in Shanghai. For a virtual booth tour and daily show highlights, visit https://www.lycra.com/en/2021Intertextile . And, LYCRA® ADAPTIV fiber will also be launched in North America to the denim industry via exclusive, invite-only virtual meetings being held on September 21-22.
Additional information on LYCRA® ADAPTIV fiber can be found by visiting this page on the LYCRA® brand website.
About The LYCRA Company
The LYCRA Company innovates and produces fiber and technology solutions for the apparel and personal care industries. Headquartered in Wilmington, Delaware, The LYCRA Company is recognized worldwide for its innovative products, technical expertise, sustainable solutions, and unmatched marketing support. The LYCRA Company owns leading consumer and trade brands: LYCRA® , LYCRA HyFit® , LYCRA® T400® , COOLMAX® , THERMOLITE® , ELASPAN® , SUPPLEX® , and TACTEL® . The LYCRA Company’s legacy stretches back to 1958 with the invention of the original spandex yarn, LYCRA® fiber. Today, The LYCRA Company focuses on adding value to its customers’ products by developing unique innovations designed to meet the consumer’s need for comfort and lasting performance. For more information, visit www.thelycracompany.com .
LYCRA® is a trademark of The LYCRA Company.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210914005789/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom